PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/9/2019 |
| Start Date: | April 2011 |
| End Date: | January 2019 |
Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse
Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer
to select patients who may benefit from directed therapy
to select patients who may benefit from directed therapy
The goal of this project is improved imaging of prostate cancer by positron emission
tomography (PET) with use of the radiopharmaceutical C-11 Acetate, utilizing state-of-the-art
PET/CT camera technology and processing algorithms.
A successful effort will lead to more accurate diagnosis of recurrence in patients with
prostate cancer to allow for early directed therapy. This study is designed to generate data
to add to the understanding of the effectiveness of C-11 Acetate, focusing on patients with
recurrent or persistent disease after prostatectomy or radiation therapy.
The study is designed to expand on the database of C11-Acetate PET imaging in patients with
prior definitive therapy for prostate cancer and evidence of biochemical recurrence (post
therapy rise in PSA), and to evaluate the relationship between detection on C11-Acetate PET
imaging, PSA (Trigger, Velocity and Doubling Time) and FDG PET imaging.
Specific questions to be addressed:
1. What is the yield of current state-of-the-art PET/CT with C-11 Acetate in detecting
recurrent disease in this patient population?
2. How does the performance of PET with C-11 Acetate compare with that of PET using F-18
fluorodeoxyglucose (FDG-PET), Sodium F18 PET bone scans and with that of CT?
3. What is the optimal imaging protocol in terms of imaging time after injection?
tomography (PET) with use of the radiopharmaceutical C-11 Acetate, utilizing state-of-the-art
PET/CT camera technology and processing algorithms.
A successful effort will lead to more accurate diagnosis of recurrence in patients with
prostate cancer to allow for early directed therapy. This study is designed to generate data
to add to the understanding of the effectiveness of C-11 Acetate, focusing on patients with
recurrent or persistent disease after prostatectomy or radiation therapy.
The study is designed to expand on the database of C11-Acetate PET imaging in patients with
prior definitive therapy for prostate cancer and evidence of biochemical recurrence (post
therapy rise in PSA), and to evaluate the relationship between detection on C11-Acetate PET
imaging, PSA (Trigger, Velocity and Doubling Time) and FDG PET imaging.
Specific questions to be addressed:
1. What is the yield of current state-of-the-art PET/CT with C-11 Acetate in detecting
recurrent disease in this patient population?
2. How does the performance of PET with C-11 Acetate compare with that of PET using F-18
fluorodeoxyglucose (FDG-PET), Sodium F18 PET bone scans and with that of CT?
3. What is the optimal imaging protocol in terms of imaging time after injection?
Inclusion Criteria:
- recurrent prostate cancer (detectable PSA following radical prostatectomy or rising
PSA in patients with radiation therapy as the primary treatment)
Exclusion Criteria:
- < 18 years old
- claustrophobic patients
We found this trial at
1
site
Click here to add this to my saved trials
